To confirm the protective role and consequences of α-lipoic acid treatment, increased S1P and SA1P levels have limited inflammation and immune responses during the progression of MASLD to MASH [23,28]. This evidence concerns the gene MBTPS1 and metabolic dysfunction-associated steatotic liver disease.